Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
24,683,081

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Mylan Suffers Several Setbacks: What's in Store in 2H18?

Mounting competition and recent setbacks cast a pall over Mylan's (MYL) near-term performance.

    Pfizer Discontinues Studies on DMD Candidate Domagrozumab

    Pfizer (PFE) terminates two clinical studies evaluating pipeline candidate, domagrozumab, in patients with duchenne muscular dystrophy.

      Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus

      Novartis (NVS) & AbbVie (ABBV) get cancer approvals. Merck (MRK) gets FDA nod for two new HIV medicines.

        Kinjel Shah headshot

        4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline

        We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.

          Pfizer (PFE) Up 3.1% Since Last Earnings Report: Can It Continue?

          Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

            Amgen's Leukemia Drug Blincyto Gets EU Nod for Pediatric Use

            Amgen's (AMGN) leukemia drug, Blincyto gets approval in EU for use in pediatric patients aged one year or older.

              Sweta Killa headshot

              Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

              Style Box ETF report for FTCS

                Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

                Pfizer (PFE) closed the most recent trading day at $41.51, moving -0.06% from the previous trading session.

                  Pfizer Stock Up This Year So Far: What's Going in its Favor?

                  Pfizer's (PFE) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

                    Pfizer's Tafamidis Fails to Impress in Cardiomyopathy Study

                    Pfizer's (PFE) tafamidis significantly reduces rate of mortality and cardiovascular-related hospitalization in patients with transthyretin amyloid cardiomyopathy. However, it fails to impress investors. Stock dips.

                      Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs

                      Allergan (AGN) gets CRL for uterine fibroids candidate, Esmya. Merck (MRK) and Bristol-Myers' (BMY) PD-L1 inhibitors get FDA approval for expanded labels.

                        Pfizer Amends Xtandi Study Protocols to Speed Up Completion

                        Pfizer (PFE) and Astellas Pharma announce amendment of protocols for two phase III studies evaluating Xtandi in hormone-sensitive prostate cancer, advancing anticipated completion date.

                          Exact Sciences Inks Cologuard Co-Promotion Deal With Pfizer

                          Exact Sciences (EXAS) reaches a co-promotion agreement with Pfizer to commercialize its non-invasive screening test for colorectal cancer, Cologuard. The stock rallies following this news.

                            Is the Options Market Predicting a Spike in Pfizer (PFE) Stock?

                            Investors need to pay close attention to Pfizer (PFE) stock based on the movements in the options market lately.

                              Glaxo Stock Up This Year So Far: Will the Rally Continue?

                              After a relatively strong performance so far this year, let's see how things are shaping up for Glaxo (GSK) for the rest of the year.

                                Roche's Lung Cancer Drug Alecensa Gets Approval in China

                                The China National Drug Administration approves Roche's (RHHBY) cancer drug Alecensa as a monotherapy for first-line treatment of advanced non-small cell lung cancer.

                                  Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic

                                  Mylan (MYL) suffers another setback as Teva wins the FDA approval of first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions.

                                    Company News For Aug 17, 2018

                                    Companies in the news are: JD, JCP, PFE and AMZN

                                      Teva Gets FDA Nod for First Generic Version of Mylan's EpiPen

                                      Teva (TEVA) gains FDA approval for the first generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment.

                                        Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study

                                        Glaxo (GSK) and Johnson and Johnson report positive top line results from a late-stage study of their injectable two-drug regimen for the treatment of HIV.

                                          Shire, Shionogi File NDA for Intuniv for Adults in Japan

                                          Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.

                                            Corcept (CORT) Earnings and Revenues Miss Estimates in Q2

                                            Corcept's (CORT) earnings and revenues lag estimates in Q2. Meanwhile, the company posts positive interim data from phase I/II study on its pipeline candidate relacorilant.

                                              Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well

                                              Aerie's (AERI) Q2 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.

                                                Sweta Killa headshot

                                                Q2 Earnings Drive Pharma ETFs Higher

                                                The string of strong results pushed pharma ETFs higher, with the four funds posting positive returns over the past one month.

                                                  The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis

                                                  The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis